文献速递妇科

ASRGL1与p53联合免疫组化作为子宫内膜样子宫内膜癌生存的独立预测因子

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2018-03-02

本研究对306例子宫内膜样子宫内膜癌标本进行组织芯片免疫组化分析,评估包括p53和ASRGL1在内的标志物组合能否独立于临床病理因素预测预后。结果显示p53与ASRGL1组合可将患者分为高危(5.9%)、中危(29.5%)和低危(64.6%)三组,高危组死于该病的风险为低危组的30倍(P<0.001)。

要点

  • p53与ASRGL1免疫组化组合是复发无生存和疾病特异性生存的最准确预测指标。
  • 该组合将患者分为高危5.9%、中危29.5%、低危64.6%三组。
  • 高危组死于子宫内膜样子宫内膜癌的风险为低危组的30倍(P<0.001)。

核心结论

  • p53与ASRGL1免疫组化组合可将子宫内膜样子宫内膜癌患者分为三个预后显著不同的风险组。
  • 该简单易行的标志物组合可能有助于子宫内膜样子宫内膜癌的风险分层和治疗方式分配。

研究设计与样本

  • 对306例子宫内膜样子宫内膜癌标本采用组织芯片进行免疫组化分析。
  • 检测标志物包括ER、PR、HER2、Ki-67、MLH1、p53、L1CAM和ASRGL1。
  • 采用嵌入变量选择的统计建模识别预后效能最大且不损害泛化性的最小预后组合。

主要发现

  • 包含p53和ASRGL1免疫组化的组合被确定为复发无生存和疾病特异性生存的最准确预测指标。
  • 该组合将患者分为高危组5.9%、中危组29.5%和低危组64.6%。
  • 高危组死于子宫内膜样子宫内膜癌的风险为低危组的30倍(P<0.001)。

关键数值与推荐

  • 高危组占5.9%,中危组占29.5%,低危组占64.6%。
  • 高危组较低危组死亡风险为30倍(P<0.001)。

临床怎么用

  • 作者认为该p53与ASRGL1免疫组化组合可能作为子宫内膜样子宫内膜癌风险分层和指导治疗分配的有用工具。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In clinical practise, prognostication of endometrial cancer is based on clinicopathological risk factors. The use of immunohistochemistry-based markers as prognostic tools is generally not recommended and a systematic analysis of their utility as a panel is lacking. We evaluated whether an immunohistochemical marker panel could reliably assess endometrioid endometrial cancer (EEC) outcome independent of clinicopathological information. METHODS: A cohort of 306 EEC specimens was profiled using tissue microarray (TMA). Cost- and time-efficient immunohistochemical analysis of well-established tissue biomarkers (ER, PR, HER2, Ki-67, MLH1 and p53) and two new biomarkers (L1CAM and ASRGL1) was carried out. Statistical modelling with embedded variable selection was applied on the staining results to identify minimal prognostic panels with maximal prognostic accuracy without compromising generalizability. RESULTS: A panel including p53 and ASRGL1 immunohistochemistry was identified as the most accurate predictor of relapse-free and disease-specific survival. Within this panel, patients were allocated into high- (5.9%), intermediate- (29.5%) and low- (64.6%) risk groups where high-risk patients had a 30-fold risk (P<0.001) of dying of EEC compared to the low-risk group. CONCLUSIONS: P53 and ASRGL1 immunoprofiling stratifies EEC patients into three risk groups with significantly different outcomes. This simple and easily applicable panel could provide a useful tool in EEC risk stratification and guiding the allocation of treatment modalities.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Huvila J, Laajala TD, Edqvist PH, et al. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma. Gynecol Oncol. 2018. PMID: 29486992. doi:10.1016/j.ygyno.2018.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。